About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Alzheimer's Disease Clinical Trials in Phoenix | 240 Studies

Clinical Trials Alzheimer's DiseasePhoenix

Alzheimer's Disease Clinical Trials in Phoenix

Find 240 clinical trials for alzheimer's disease near Phoenix, Arizona. Connect with research centers in your area.

All Alzheimer's Disease trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 81-100 of 240 trials

CompletedPhase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the BrainThe study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at…NCT00857415·Phoenix, Arizona and 24 others TerminatedA Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study…NCT00937352·Birmingham, Alabama and 190 others

Alzheimer's Disease Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedEfficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's DiseaseThe primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to treat dementia.NCT00663936·Phoenix, Arizona and 34 others

TerminatedStudy Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer DiseaseThe study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels.NCT00895895·Phoenix, Arizona and 95 others

Enrolling by invitationThe Diabetes Prevention Program Outcomes Study AD/ADRD ProjectThe DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2…NCT05704309·Phoenix, Arizona and 26 others

CompletedA Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's DiseaseAZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation.NCT02167256·Phoenix, Arizona and 21 others

CompletedApathy in Dementia Methylphenidate Trial 2Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, multi-center randomized clinical trial sponsored by National Institutes…NCT02346201·Phoenix, Arizona and 9 others

CompletedA Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment…NCT00702143·Phoenix, Arizona and 14 others

CompletedEfficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC.NCT02079909·Phoenix, Arizona and 49 others

RecruitingA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis…NCT06585787·Chandler, Arizona and 295 others

TerminatedSafety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal…NCT03443973·Phoenix, Arizona and 154 others

TerminatedEvaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's DiseaseThis is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease.NCT02080364·Phoenix, Arizona and 114 others

CompletedStudy Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseTo access the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in subjects with mild to moderate Alzheimer's disease.NCT00498602·Phoenix, Arizona and 26 others

CompletedEfficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)Alzheimer's disease is the most common form of dementia and is the fourth leading cause of death among people 65 years of age and older.NCT01466088·Phoenix, Arizona and 32 others

CompletedAssessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeThis study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the…NCT03393520·Chandler, Arizona and 210 others

CompletedAnalysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD SubjectsA Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI…NCT02016560·Phoenix, Arizona and 26 others

Enrolling by invitationAlzheimer's Disease Neuroimaging Initiative 4The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design…NCT05617014·Birmingham, Alabama and 64 others

CompletedA Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseThe main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer…NCT06538116·Phoenix, Arizona and 63 others

CompletedA Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's AgitationTo compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.NCT01862640·Tuscaloosa, Alabama and 84 others

CompletedOpen-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's DiseaseThis is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's…NCT00381238·Litchfield Park, Arizona and 6 others

PreviousPage 5 of 12Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia